Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study-Reference-Cited by-同舟云学术

Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study

Published:2022-01 Issue:1 Volume:20 Page:88-95
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Vedamurthy Amar,Gangasani Nikitha,Ananthakrishnan Ashwin N.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Inflammatory bowel disease;Abraham;N Engl J Med,2009

2. Complications of biologics in inflammatory bowel disease;Sousa;Curr Opin Gastroenterol,2015

3. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis;Shelton;Gastroenterology,2016

4. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC Success Trial;Panccione;Gastroenterology,2011

5. Management of inflammatory bowel disease in the elderly patient: challenges and opportunities;Ananthakrishnan;Inflamm Bowel Dis,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023;Intestinal Research;2024-07-31

2. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary;Clinical Gastroenterology and Hepatology;2024-07

3. The difficulties of differential diagnosis of Crohn’s disease and metastatic breast cancer (case report);Koloproktologia;2024-06-21

4. Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry;Clinical Gastroenterology and Hepatology;2024-05

5. Progress in understanding of relationship between use of biological agents and risk of malignant tumors in patients with inflammatory bowel disease;World Chinese Journal of Digestology;2024-03-28